Selexis Named One of the "Best Companies to Work for in Switzerland 2018"

Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, was named one of the best employers in the "Best Companies to Work for in Switzerland 2018" study carried out by Great Place to Work^®. The award, announced last evening at an awards gala hosted by Great Place to Work Switzerland research institute, recognizes companies of all sizes from all industries whose employees think they have an especially trustworthy, appreciative and attractive workplace culture.

"Achieving this distinction from Great Place to Work is especially meaningful because it is essentially being awarded to us by our employees – the greatest asset we have in our efforts to help enable biopharmaceutical companies to bring life-saving medicines to patients in need," said Igor Fisch, PhD, Selexis chief executive officer. "This award recognizes both what we're doing well at the company, and it also helps us pinpoint areas where we can improve and grow. I am so incredibly proud of what we have accomplished with such a small team of driven, talented employees. I offer sincere thanks to Great Place to Work Switzerland for the recognition, and to my Selexis family members for their knowledge, loyalty and commitment to Selexis' success."

Selexis achieved an exceptional trust index of 89% in the employee satisfaction questionnaire. A full 96% of Selexis employees agreed with the statement: "Taking everything into account, I would say this is a great place to work." 100% of Selexis employees "care about each other, find Selexis a friendly place to work, feel that when they join the organization they are made to feel welcome, feel there is a ‘family' or ‘team' feeling here and feel ‘we are in this together.'"

The research institute analyses a company's attractiveness in a two-step process. First, Selexis employees are surveyed anonymously on central workplace topics such as trust, identification, team spirit, professional development, remuneration, health support and work-life balance. Second, the company's HR processes and corporate culture are subjected to a peer-reviewed audit. Scores from the survey and the culture audit were used to rank the winners.

"The award stands for a workplace culture especially defined by trust, pride and team spirit," says Michael Hermann, CEO of Great Place to Work^® Switzerland. "Trust-based relationships in the workplace and attractive working conditions are key in motivating and encouraging loyalty in qualified employees as well as the company's economic success and future viability."

On May 3, 2018, Selexis and its co-founders were recognized by the Swiss Biotech Association among its inaugural group of Swiss Biotech Success Stories as determined by a jury of industry experts, based upon the company's contributions to the biotechnology industry in Switzerland.

About Great Place to Work

Great Place to Work is a consultancy with branches in almost 50 countries. As well as employee surveys and culture analyses, Great Place to Work® supports companies in their development towards becoming excellent employers. The Great Place to Work® top employer list involves around 10,000 surveyed companies each year, making it the best-known and biggest initiative to improve workplace culture. Great Place to Work® Switzerland was founded in Zurich in 2008. The national benchmark competition ‘Best Companies to Work for in Switzerland' has been carried out each year since 2009, and involves companies of all sizes from all industries and regions. You can find more information on www.greatplacetowork.ch.

About Selexis SA

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis' SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, more than 100 drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.

FOR MORE INFORMATION

View source version on businesswire.com: https://www.businesswire.com/news/home/20180517005643/en/